EGFR and non-small cell lung carcinoma: As an example, the combination of chemotherapy and EGFR inhibitors has proved efficacy in SC models of NSCLC [27], [28], but has never reached significant efficacy in clinical trials including unselected NSCLC patients upon EGFR status [3], [10], [29].